Facilitated By

San Antonio Medical Foundation

SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.

The University of Texas at San Antonio

The University of Texas at San Antonio is an emerging Tier One research institution with nearly 29,000 students.

Principal Investigator(s)
Hung, Chiung-Yu
Lopez-Ribot, Jose
Yu, Jieh-Juen
Funded by
NIH Natl Inst of Allergy/Infectious Dise
Research Start Date

This CCRC U19 proposal is composed of 1 administrative core. 3 scientific projects and 2 scientific cores.We have assembled a team of experts to develop novel therapeutic drugs and vaccines against coccidioidomycosis.The Co-PI/PDs are Dr. Chiung-Yu Hung and Jose Lopez-Ribot
 The 3 projects are:
 1. Project#1
 Title: Screening repurposing libraries for the identification of drugs with novel anti-coccidioidal activity
 Co-Leads: Dr. Jose Lopez-Ribot and Dr. Jieh-Juen Yu at Biology Department. UTSA
 2. Project#2
 Title: Relationship between in vitro antifungal resistance and in vivo response in coccidioidomycosis
 Co-Leads: Dr. Thomas Patterson and Dr. Nathan Wiederhold at UT Health San Antonio
 3. Project#3
 Title: Active vaccination and immunotherapy against coccidioidomycosis
 Lead: Dr. Chiung-Yu Hung at UTSA. 
 The 2 scientific cores are
 1. BSL3 drug screening core. Lead: Dr. Jose Lopez-Ribot
 2. Cell-Genomics-Bioinformatics core. Co-Leads: Dr. Astrid Cardona. Dr. Brian Herman and Dr. Yufeng Wang. 

Collaborative Project
Basic Research
Drug Discovery
Infectious Disease